Therapeutic anti-melanoma compounds

• US 20020082217A1
• Filed: 05/21/2001
• Published: 06/27/2002
• Est. Priority Date: 05/31/2000
• Status: Active Grant

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Nicolette, Charles A.
• Granted Patent: US 6,861,408 B2
• Time in Patent Office: Days
• US Class Current: 514/15
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 39/461 characterised by the cell type used
• CPC Class Codes: A61K 39/4622 Antigen presenting cells
• CPC Class Codes: A61K 39/464 characterised by the antigen targeted or presented
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.

Claims

1. A compound having the structure:

32. An antibody that specifically recognizes and binds a compound of any of claims 1 to 10.

33. A method for inducing an immune response in a subject, comprising delivering an effective amount of a compound of any of claims 1 to 10 to the subject.

34. The method of claim 33, wherein the compound is delivered in the context of an MHC molecule.

35. The method of claim 33, wherein the MHC molecule presents the compound on the surface of an antigen presenting cell.

36. The method of claim 33, wherein the compound is delivered as a polynucleotide that encodes the compound.

37. A method of immunotherapy, comprising administering to a subject an effective amount of an antibody of claim 32.

38. An immune effector cell that has been raised in vitro or in vivo in the presence and at the expense of an antigen presenting cell that presents the compound of any of claims 1 to 10 in the context of an MHC molecule.

39. A method of adoptive immunotherapy, comprising administering an effective amount of the immune effector cell of claim 38.

2. A compound having the structure:

3. A compound having the structure:

4. A compound having the structure:

5. A compound having the structure:

6. A compound having the structure:

7. A compound having the structure:

8. A compound having the structure:

9. A compound having the structure:

10. A compound having the structure:

11. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 and 210 are F, and L respectively.

31. A polynucleotide that encodes a peptide of any of claims 11 to 20.

12. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209, 210, and 213, are F, L, and A respectively.

13. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209, 210, 213 and 216 are F, L, A and V, respectively.

14. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209, 210, 211, 212, 213, 214, and 216 are F, L, F, L, W, F and E, respectively.

15. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209, 210, 213, 214, and 216 are F, L, R, V, and V, respectively.

16. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209, 210, 211, 212, 213, 215 and 216, are F, L, T, M, W. G and G, respectively.

17. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 through 216, are F, L, S, W, E, G, L and V, respectively.

18. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 through 216 are F, L I, W, E, G, Y and V, respectively.

19. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209, 210, 212, 214, 215, and 216 are F, L, S, F, N, and L, respectively.

20. A peptide comprising the amino acid sequence of SEQ ID NO:

2 wherein amino acids 209 through 216, are F, L, L, W, E, G, L, and V, respectively.

21. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

3.

22. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

5.

23. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

7.

24. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

9.

25. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

11.

26. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

13.

27. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

15.

28. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

17.

29. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

19.

30. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO:

21.